BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 24647021)

  • 21. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis.
    Hidalgo-Tenorio C; Gálvez J; Martínez-Marcos FJ; Plata-Ciezar A; De La Torre-Lima J; López-Cortés LE; Noureddine M; Reguera JM; Vinuesa D; García MV; Ojeda G; Luque R; Lomas JM; Lepe JA; de Alarcón A
    BMC Infect Dis; 2020 Feb; 20(1):160. PubMed ID: 32085732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
    Sader HS; Becker HK; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter?
    Ruiz-Ramos J; Vidal-Cortés P; Díaz-Lamas A; Reig-Valero R; Roche-Campo F; Del Valle-Ortiz M; Nuvials-Casals X; Ortiz-Piquer M; Andaluz-Ojeda D; Tamayo-Lomas L; Blasco-Navalpotro MA; Rodriguez-Aguirregabiria M; Aguado J; Ramirez P
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1569-1575. PubMed ID: 28378244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High vancomycin minimum inhibitory concentration is associated with poor outcome in patients with methicillin-susceptible Staphylococcus aureus bacteremia regardless of treatment.
    Castón JJ; González-Gasca F; Porras L; Illescas S; Romero MD; Gijón J
    Scand J Infect Dis; 2014 Nov; 46(11):783-6. PubMed ID: 25134647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of vancomycin plus cloxacillin compared with vancomycin, cloxacillin and daptomycin single therapies in the treatment of methicillin-resistant and methicillin-susceptible Staphylococcus aureus in a rabbit model of experimental endocarditis.
    Castañeda X; García-De-la-Mària C; Gasch O; Pericàs JM; Soy D; Cañas-Pacheco MA; Falces C; García-González J; Hernández-Meneses M; Vidal B; Almela M; Quintana E; Tolosana JM; Fuster D; Llopis J; Dahl A; Moreno A; Marco F; Miró JM;
    J Antimicrob Chemother; 2021 May; 76(6):1539-1546. PubMed ID: 33837406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No effect of vancomycin MIC ≥ 1.5 mg/L on treatment outcome in methicillin-susceptible Staphylococcus aureus bacteraemia.
    Bouiller K; Laborde C; Aho SL; Hocquet D; Pechinot A; Le Moing V; Bertrand X; Piroth L; Chirouze C
    Int J Antimicrob Agents; 2018 May; 51(5):721-726. PubMed ID: 29305961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies.
    Keel RA; Sutherland CA; Aslanzadeh J; Nicolau DP; Kuti JL
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):326-9. PubMed ID: 20955917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
    Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
    Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.
    Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Warren SJ; Gao W; Johnson PD; Howden BP
    Clin Microbiol Infect; 2013 Dec; 19(12):1163-8. PubMed ID: 23441652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.
    Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Gao W; Christiansen KJ; Coombs GW; Johnson PD; Howden BP
    J Infect Dis; 2011 Aug; 204(3):340-7. PubMed ID: 21742831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.
    Lodise TP; McKinnon PS; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3731-3. PubMed ID: 17664322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
    Ruggero MA; Peaper DR; Topal JE
    Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
    Brown J; Brown KA; Forrest A
    Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
    Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
    J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report.
    Jongsma K; Joson J; Heidari A
    J Antimicrob Chemother; 2013 Jun; 68(6):1444-5. PubMed ID: 23341127
    [No Abstract]   [Full Text] [Related]  

  • 40. Glycopeptide and daptomycin susceptibility trends among clinical isolates of methicillin-resistant Staphylococcus aureus in a tertiary care center in North India.
    Singh A; Prasad KN; Rai RP; Singh SK; Rahman M; Tripathi A; Srivastava JK
    J Infect Public Health; 2015; 8(4):341-5. PubMed ID: 25797814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.